BIOXYNE LIMITED — Capital/Financing Update 2011

Nov 2, 2011

==> picture [218 x 51] intentionally omitted <==

Probiomics Limited ABN 97 084 464 193

Suite 1A, Level 2 802 Pacific Highway Gordon NSW 2072

Australian Securities Exchange Companies Announcements Office SYDNEY

P: +61 2 9844 5422 F: +61 2 9844 5445 W: www.probiomics.com.au

3[rd] November 2011

EXCLUDED OFFER

Probiomics Limited (“Probiomics” ASX Code:PCC) is pleased to announce that it will raise $200,000 by the issue of 33,333,334 shares at $0.006 per share as an excluded offer through a private placement of shares to professional and sophisticated investors (“Excluded Offer”). These shares will be classified as restricted securities and will not be able to trade until the Re-admission of the Company.

The funds raised through the placement will be used to pay for the professional costs and disbursements related to the proposed acquisition of Hunter Immunology Limited announced on the 11 October 2011, related public capital raising and the subsequent application for re-admission of Probiomics to the Official List of ASX.

The Excluded Offer has been underwritten by Veritas Securities Limited and Taylor Collison Limited on a best endeavours basis and is being undertaken pursuant to Section 708 of the Corporations Act (Cwth) 2001.

CONTACT

Mr Ashok Jairath - Chief Financial Officer and Company Secretary Tel: +612 9844 5422 Email ashok.jairath@probiomics.com.au

1

==> picture [218 x 51] intentionally omitted <==

==> picture [36 x 36] intentionally omitted <==

About Probiomics Limited

Probiomics has proprietary ownership of a unique probiotic strain – PCC[® ]

PCC[®] has been clinically proved to have superior qualities – particularly in promoting systemic immune response.

Probiomics’ commercial objective is to earn royalties from licensing PCC[®] to distribution companies selling products in global markets.

For further information, please go to www.probiomics.com.au

2